Candidemia in Patients With Cardiovascular Implantable Electronic Devices : Uncertainty in Management Based on Current International Guidelines
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Background: In contrast to bloodstream infection due to a variety of bacteria in patients with cardiovascular implantable electronic devices (CIED), there are limited data regarding candidemia and risk of CIED infection.
Methods: All patients with candidemia and a CIED at Mayo Clinic Rochester between 2012 and 2019 were reviewed. Cardiovascular implantable electronic device infection was defined by (1) clinical signs of pocket site infection or (2) echocardiographic evidence of lead vegetations.
Results: A total of 23 patients with candidemia had underlying CIED; 9 (39.1%) cases were community onset. None of the patients had pocket site infection. The duration between CIED placement and candidemia was prolonged (median 3.5 years; interquartile range, 2.0-6.5). Only 7 (30.4%) patients underwent transesophageal echocardiography and 2 of 7 (28.6%) had lead masses. Only the 2 patients with lead masses underwent CIED extraction, but device cultures were negative for Candida species. Two (33.3%) of 6 other patients who were managed as candidemia without device infection subsequently developed relapsing candidemia. Cardiovascular implantable electronic device removal was done in both patients and device cultures grew Candida species. Although 17.4% of patients were ultimately confirmed to have CIED infection, CIED infection status was undefined in 52.2%. Overall, 17 (73.9%) patients died within 90 days of diagnosis of candidemia.
Conclusions: Although current international guidelines recommend CIED removal in patients with candidemia, the optimal management strategy remains undefined. This is problematic because candidemia alone is associated with increased morbidity and mortality as seen in this cohort. Moreover, inappropriate device removal or retention can both result in increased patient morbidity and mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 10(2023), 7 vom: 01. Juli, Seite ofad318 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chesdachai, Supavit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Candidemia |
|---|
| Anmerkungen: |
Date Revised 18.07.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofad318 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359279961 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359279961 | ||
| 003 | DE-627 | ||
| 005 | 20231226080533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofad318 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359279961 | ||
| 035 | |a (NLM)37426953 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chesdachai, Supavit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Candidemia in Patients With Cardiovascular Implantable Electronic Devices |b Uncertainty in Management Based on Current International Guidelines |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Background: In contrast to bloodstream infection due to a variety of bacteria in patients with cardiovascular implantable electronic devices (CIED), there are limited data regarding candidemia and risk of CIED infection | ||
| 520 | |a Methods: All patients with candidemia and a CIED at Mayo Clinic Rochester between 2012 and 2019 were reviewed. Cardiovascular implantable electronic device infection was defined by (1) clinical signs of pocket site infection or (2) echocardiographic evidence of lead vegetations | ||
| 520 | |a Results: A total of 23 patients with candidemia had underlying CIED; 9 (39.1%) cases were community onset. None of the patients had pocket site infection. The duration between CIED placement and candidemia was prolonged (median 3.5 years; interquartile range, 2.0-6.5). Only 7 (30.4%) patients underwent transesophageal echocardiography and 2 of 7 (28.6%) had lead masses. Only the 2 patients with lead masses underwent CIED extraction, but device cultures were negative for Candida species. Two (33.3%) of 6 other patients who were managed as candidemia without device infection subsequently developed relapsing candidemia. Cardiovascular implantable electronic device removal was done in both patients and device cultures grew Candida species. Although 17.4% of patients were ultimately confirmed to have CIED infection, CIED infection status was undefined in 52.2%. Overall, 17 (73.9%) patients died within 90 days of diagnosis of candidemia | ||
| 520 | |a Conclusions: Although current international guidelines recommend CIED removal in patients with candidemia, the optimal management strategy remains undefined. This is problematic because candidemia alone is associated with increased morbidity and mortality as seen in this cohort. Moreover, inappropriate device removal or retention can both result in increased patient morbidity and mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a candidemia | |
| 650 | 4 | |a cardiovascular implantable electronic device | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a outcome | |
| 650 | 4 | |a relapse | |
| 700 | 1 | |a Baddour, Larry M |e verfasserin |4 aut | |
| 700 | 1 | |a Sohail, M Rizwan |e verfasserin |4 aut | |
| 700 | 1 | |a Palraj, Bharath Raj |e verfasserin |4 aut | |
| 700 | 1 | |a Madhavan, Malini |e verfasserin |4 aut | |
| 700 | 1 | |a Tabaja, Hussam |e verfasserin |4 aut | |
| 700 | 1 | |a Fida, Madiha |e verfasserin |4 aut | |
| 700 | 1 | |a Challener, Douglas W |e verfasserin |4 aut | |
| 700 | 1 | |a DeSimone, Daniel C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 10(2023), 7 vom: 01. Juli, Seite ofad318 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:7 |g day:01 |g month:07 |g pages:ofad318 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofad318 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 7 |b 01 |c 07 |h ofad318 | ||